Market Newsdesk

Patent issuance expands United States patent coverage for AVERSA™ transdermal abuse deterrent technology

AVERSA™ transdermal abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

ORLANDO, Fla., June 09, 2025 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that the United States Patent and Trademark Office (USPTO) issued patent number 12,318,492 on June 3, 2025, entitled “Abuse and Misuse Deterrent Transdermal Systems.”
The issuance of this patent further expands Nutriband’s intellectual property protection in the United States for its portfolio of abuse deterrent transdermal products based on its proprietary Aversa™ abuse deterrent technology. This technology can be incorporated into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential.

The AVERSA™ abuse deterrent technology is protected by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

Nutriband’s lead product under development is Aversa™ Fentanyl, an abuse deterrent fentanyl transdermal system, with the potential to become the first abuse deterrent pain patch on the market with peak annual US sales estimated to be$80 million to $200 million.¹

__________________________________________

¹ Health Advances Aversa Fentanyl market analysis report 2022

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband’s AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘’believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Forms 10-K and 10-Q’s, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:

Nutriband Inc.
Phone: 407-377-6695
Email: [email protected]

HOUSTON, TX, June 09, 2025 (GLOBE NEWSWIRE) — Prairie Operating Co. (Nasdaq: PROP) (the “Company” or “Prairie”), an independent energy company engaged in the development and acquisition of oil and natural gas resources in the Denver-Julesburg (DJ) Basin, today announced the reaffirmation of its multi-year Reserve-Based Lending (“RBL”) credit facility with Citibank, N.A., its lead arranger.

Following its semi-annual redetermination, the Company’s reserve-based credit facility was reaffirmed with a borrowing base of $475 million, a maximum facility size of $1.0 billion, and a maturity date of March 26, 2029.

“The reaffirmation of our borrowing base, along with the addition of Bank of America and West Texas National Bank to our syndicate, underscores the confidence our lenders have in the strength of our asset base and execution strategy,” said Edward Kovalik, Chairman and Chief Executive Officer. “This facility enhances our financial flexibility and supports our ongoing development activity and pursuit of accretive growth opportunities in the DJ Basin.”

In conjunction with the semi-annual redetermination, Bank of America, N.A. and West Texas National Bank have joined the lending syndicate, which includes Citibank, N.A., KeyBank National Association, MUFG Bank, Ltd., Truist Bank, UMB Bank, N.A., and Macquarie Bank Limited, further expanding Prairie’s banking relationships and strengthening its access to capital.

About Prairie Operating Co.

Prairie Operating Co. is a Houston-based publicly traded independent energy company engaged in the development and acquisition of oil and natural gas resources in the United States. The Company’s assets and operations are concentrated in the oil and liquids-rich regions of the Denver-Julesburg (DJ) Basin, with a primary focus on the Niobrara and Codell formations. The Company is committed to the responsible development of its oil and natural gas resources and is focused on maximizing returns through consistent growth, capital discipline, and sustainable cash flow generation. More information about the Company can be found at www.prairieopco.com.

Cautionary Statement about Forward-Looking Statements

The information included herein and in any oral statements made in connection herewith include “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included herein, are forward-looking statements. When used herein, including any oral statements made in connection herewith, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on the Company’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date hereof. The Company cautions you that these forward-looking statements are subject to risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. There may be additional risks not currently known by the Company or that the Company currently believes are immaterial that could cause actual results to differ from those contained in the forward-looking statements. Additional information concerning these and other factors that may impact the Company’s expectations can be found in the Company’s periodic filings with the Securities and Exchange Commission (the “SEC”), including the Company’s Annual Report on Form 10-K filed with the SEC on March 6, 2025, and any subsequently filed Quarterly Report and Current Report on Form 8-K. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. 

Investor Relations Contact:

Wobbe Ploegsma
[email protected]
832.274.3449

• D-PLEX
  
  ₁₀₀
  
  successfully met the primary efficacy endpoint, with statistically significant results (p<0.005) in 798 patients with large abdominal surgery incisions.
• The trial successfully met all key secondary efficacy endpoints, including a 58% reduction in the rate of surgical site infections (“SSI”) in patients treated with D-PLEX₁₀₀ arm versus standard of care (“SoC”) arm (p<0.005).
  
• The Company expects to
  submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in early 2026, with a Marketing Authorization Application (“MAA”) in the E.U. to follow shortly thereafter.
  
• PolyPid will conduct a conference call and webcast at 8:30 A.M. ET today.

PETACH TIKVA, Israel, June 09, 2025 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced positive topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX₁₀₀ for the prevention of SSIs in patients undergoing abdominal colorectal surgery with large incisions, which has received Fast Track designation from the FDA.

“The positive results of our Phase 3 pivotal trial provide clear and compelling evidence of D-PLEX₁₀₀’s ability to significantly reduce SSIs, a major burden on patients and healthcare systems, while improving clinical outcomes for both patients and physicians,” said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. “D-PLEX₁₀₀ has the potential to meaningfully lower costs for hospitals and payers, and we believe it will be a valuable addition to the standard of care. Targeting a total addressable U.S. market of over 12 million annual surgeries and a significant unmet need, D-PLEX₁₀₀ has the potential to make a substantial market impact. We remain on track for an NDA submission in early 2026 and believe these robust data will serve as a strong catalyst for advancing our global partnership discussions. We are deeply grateful to the patients, principal investigators, and study teams who made this milestone possible.”

Key findings from SHIELD II study include:

• The primary efficacy endpoint of the study was successfully met, with a significantly lower proportion of primary endpoint events among patients who received D-PLEX₁₀₀ plus SoC (n=405; 10.9%), compared to SoC alone (n=393; 18.1%), representing a 38% reduction (p<0.005). The primary endpoint is the combination of deep and superficial SSIs, all-cause mortality and surgical reinterventions at the same incision of the original index surgery.
• SHIELD II included three key secondary endpoints:
  • The first key secondary endpoint was met, with a 58% reduction in deep and superficial SSI rates among patients who received D-PLEX₁₀₀ plus SoC (3.8%) compared to those who received SoC alone (9.5%) (p<0.005).
  • The second key secondary endpoint showed statistical significance in favor of D-PLEX₁₀₀ plus SoC over SoC alone (p<0.005). This efficacy endpoint combined SSI, mortality and reintervention as evaluated in the primary endpoint. This endpoint was assessed in the overall study population of 975 patients with an incision ≥7 cm, including laparoscopic surgery patients enrolled prior to the 2023 trial protocol change.
  • The third key secondary endpoint was met with a 62% reduction of patients with an ASEPSIS¹ score >20 in D-PLEX₁₀₀ plus SoC arm compared to SoC alone arm (p<0.05). The ASEPSIS score is a clinical tool used to objectively assess surgical wound infections.
• There were no safety concerns raised by the independent Data Safety Monitoring Board in SHIELD II.

Image: SHIELD II Results on Primary Endpoint and First Key Secondary Endpoint

“The risk of surgical site infection in the colorectal patient population has recently been documented to approach 23%² in patients with multiple comorbid risk factors,” said Charles E. Edmiston, Jr., MS, PhD, CIC, FIDSA, FSIS, FAPIC Emeritus Professor of Surgery. “These topline results provide clinical practitioners with a novel, innovative strategy for reducing postoperative infection risk in patients undergoing colorectal surgery with large wound incisions. Based on the trial findings, particularly the significant risk-reduction benefit by reducing in-wound sepsis risk, I anticipate D-PLEX₁₀₀ technology will be rapidly embraced as a critical component to the current evidence-based surgical care bundle for colorectal surgery following FDA approval.”

Additional results from the SHIELD II trial will be presented at an upcoming medical conference.

Conference Call Dial-In & Webcast Information:

A replay of the presentation will be available on the Company’s Investor Relations Events and Presentations webpage following the event.

About SHIELD II

SHIELD II (Surgical site Hospital acquired Infection prEvention with Local D-PLEX) is a prospective, multinational, randomized, double blind Phase 3 trial designed to assess the efficacy and safety of D-PLEX₁₀₀ administered concomitantly with standard of care (“SoC”), which includes prophylactic systemic antibiotics, compared to SoC alone arm, in the prevention of post abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The primary endpoint of the trial is measured by the proportion of subjects with either a surgical site infection (“SSI”) event as determined by a blinded and independent adjudication committee, reintervention, or mortality for any reason within 30 days post-surgery. Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe and Israel.

About D-PLEX
₁₀₀

D-PLEX_100, PolyPid’s lead product candidate, is designed to provide local prolonged and controlled anti-bacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX₁₀₀ into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for a period of 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. D-PLEX₁₀₀ received Breakthrough Therapy designation from the U.S. Food and Drug Administration for the prevention of SSIs in patients undergoing elective colorectal surgery. D-PLEX₁₀₀ is currently in Phase 3 SHIELD II trial for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX₁₀₀ is in a Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.
For additional Company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

Forward-looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the safety, efficacy and benefits of D-PLEX₁₀₀, D-PLEX₁₀₀’s potential to meaningfully lower costs for hospitals and payers, the expected submissions of an NDA to the FDA and MAA and the timing thereof; the Company’s belief that the data results will serve as a strong catalyst for advancing its global partnership discussions; D-PLEX₁₀₀ potential to make a substantial market impact; and the anticipation that D-PLEX₁₀₀ technology will be rapidly embraced as a critical component to the current evidence-based surgical care bundle for colorectal surgery following FDA approval. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission, including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed on February 26, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts:

PolyPid Ltd. 
Ori Warshavsky
COO – US
908-858-5995
[email protected]

Investors:

Brian Ritchie
LifeSci Advisors
212-915-2578
[email protected]

¹ ASEPSIS is an acronym of wound assessment and treatment parameters, which provides a numerical score during an inspection of the surgical site. The final score is interpreted by the severity of wound appearance and the clinical consequences of the infection. Parameters include: serous exudate, erythema, purulent exudate, separation of deep tissue and also antibiotic therapy, drainage of pus under local/general anesthesia, isolation of pathogenic bacteria and hospital stay as inpatient.
² David J. Leaper, D.Sc., M.D., Chantal E. Holy, M.Sc., Ph.D., Maureen Spencer, M.Ed., Abhishek Chitnis, Ph.D., Andrew Hogan, M.Sc., George W.J. Wright, Ph.D., Brian Po-Han Chen, Sc.M., Charles E. Edmiston, Jr, Ph.D. Assessment of the Risk and Economic Burden of Surgical Site Infection Following Colorectal Surgery Using a US Longitudinal Database: Is There a Role for Innovative Antimicrobial Wound Closure Technology to Reduce the Risk of Infection? Dis Colon Rectum 2020; 63:1628-1638.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/1a883ef3-5e5a-4ffc-8532-b9f87784ef42

TEL AVIV, Israel, June 09, 2025 (GLOBE NEWSWIRE) — Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of web data collection solutions, today announced an update to its revenue and Adjusted EBITDA outlook for the second quarter ending June 30, 2025, driven by enhanced momentum and demand from several existing customers since the previous guidance date, which has led to a significant increase in usage – resulting in higher-than-anticipated consumption of Alarum’s data collection products and services.

The Company now estimates to report second quarter 2025 revenue of approximately $8.8 million ±3%, compared to its previous estimate of $7.9 million ±3%. In addition, the Company now expects to report adjusted EBITDA ranging from $1.0 million to $1.5 million, compared to $0.5 million to $0.8 million.  As previously highlighted, the market in which the Company operates is still taking shape and at this point continues to be highly dynamic and unpredictable. Volatility may remain high, and the Company is planning accordingly.

The Company is unable to present a reconciliation of its estimated adjusted EBITDA to net profit as it is unable to predict with reasonable certainty, and without unreasonable effort, the impact and timing of certain expenses on the Company’s net profit. The financial impact of these expenses is uncertain and is dependent on various factors, including timing, and could be material to the Company’s consolidated statements of profit or loss and other comprehensive income (loss).

This update is provided in accordance with the Company’s internal policy of  issuing an update as its current quarterly revenue outlook is expected to deviate by at least 10% from the previously announced average of the outlook.  

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, Alarum is using forward-looking statements in this press release when it provides updated estimates regarding second quarter 2025 revenues and Adjusted EBITDA, whether the recent surge in usage will continue in subsequent periods and potential volatility. Because such statements deal with future events and are based on Alarum’s current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of Alarum could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in Alarum’s annual report on Form 20-F filed with the Securities and Exchange Commission (“SEC”) on March 20, 2025, and in any subsequent filings with the SEC. Except as otherwise required by law, Alarum undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Alarum is not responsible for the contents of third-party websites.

The Company is providing revenue and adjusted EBITDA estimates in this press release, rather than final amounts, primarily because the financial closing process and review are not yet complete and, as a result, the Company’s final results upon completion of its closing process and review may vary from these preliminary estimates.

INVESTOR RELATIONS CONTACT:

[email protected]

Plug Power and Allied Green Leadership attending International Investment Forum to Execute the Agreement

Allied Green Continues to Make Meaningful Progress in its Green Ammonia Plant in Australia with Plug to supply 3GW of Electrolyzer Capacity Bringing the total opportunity between partners to 5GW globally

SLINGERLANDS, N.Y., June 09, 2025 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions, today announced a significant expansion of its partnership with Allied Green Ammonia (AGA), with a new 2 gigawatt (GW) electrolyzer opportunity tied to a sustainable fuels project in Uzbekistan. The deal will be executed during the Tashkent International Investment Forum, where Sanjay Shrestha, President of Plug, and Alfred Benedict, Managing Director of Allied Green, will be on site for the official signing.

Plug’s electrolyzer technology has been selected as the foundation of a new $5.5 billion green chemical production facility in Uzbekistan that will produce sustainable aviation fuel, green urea, and green diesel. The project is backed by the Government of Uzbekistan and further strengthens Plug’s position as the preferred electrolyzer provider for global-scale decarbonization initiatives.

“This latest expansion with Allied Green demonstrates how Plug is leading the global hydrogen transition with proven electrolyzer technology and execution at industrial scale,” said Andy Marsh, CEO of Plug. “With a 5 GW partnership now spanning two continents, this is a defining example of our ability to deliver for customers building the future of energy.”

“This agreement reflects our deep confidence in Plug’s team, technology, and ability to deliver on bold, world-class projects,” said Alfred Benedict of Allied Green Ammonia. “Together, we are creating meaningful momentum for global decarbonization—first in Australia, now in Uzbekistan, and in future regions to come.”

The Uzbekistan project builds on Allied Green’s previously announced 3 GW electrolyzer commitment for its flagship green ammonia facility in Australia. The project remains on track for a final investment decision in the fourth quarter of 2025.

“This continued collaboration with Allied Green reflects Plug’s ability to support ambitious decarbonization goals with scalable electrolyzer technology,” said Sanjay Shrestha, President of Plug. “As we look to expand our relationship, we see strong alignment in our shared vision for accelerating the global shift to low-carbon hydrogen across industries and regions.”

Plug’s technology is deployed or under development across five continents, supporting customers in the industrial, transportation, energy, and chemical sectors. As global companies invest in green hydrogen infrastructure, Plug continues to stand out as the most experienced and scalable partner—delivering the integrated hydrogen ecosystem necessary to power the energy transition.

About Plug Power

Plug is building the global hydrogen economy with a fully integrated ecosystem spanning production, storage, delivery, and power generation. A first mover in the industry, Plug provides electrolyzers, liquid hydrogen, fuel cell systems, storage tanks, and fueling infrastructure to industries such as material handling, industrial applications, and energy producers—advancing energy independence and decarbonization at scale.

With electrolyzers deployed across five continents, Plug leads in hydrogen production, delivering large-scale projects that redefine industrial power. The company has deployed over 72,000 fuel cell systems and 275 fueling stations and is the largest user of liquid hydrogen. Plug is rapidly expanding its generation network to ensure reliable, domestically produced supply, with hydrogen plants currently operational in Georgia, Tennessee, and Louisiana, capable of producing 39 tons per day.

With employees and state-of-the-art manufacturing facilities across the globe, Plug powers global leaders like Walmart, Amazon, Home Depot, BMW, and BP.

Safe Harbor

This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Plug Power Inc. (“Plug”), including but not limited to statements about Plug’s commercial arrangements, agreements or contracts, if any, with Allied Green Ammonia (“AGA”), including actual execution of binding agreements, expected timing for any Plug delivery of any equipment, products or services under any commercial contracts or other arrangements or Plug’s ability to receive any revenue or payment on such product, equipment or services; AGA’s plans for its green ammonia production facility, including its ability to execute on any plans including stated production capacity and timing of FID, as well as any actual or continued government support for such projects or programs. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Plug in general, see Plug’s public filings with the Securities and Exchange Commission (the “SEC”), including the “Risk Factors” section of Plug’s Annual Report on Form 10-K for the year ended December 31, 2024, Plug’s Quarterly Reports on Form 10-Q for the quarter ended March 31, 2025 and any subsequent filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements are made as of the date hereof, and Plug undertakes no obligation to update such statements as a result of new information.

MEDIA CONTACT

Teal Hoyos
[email protected]